Valneva SE (EPA:VLA)
3.820
+0.044 (1.17%)
At close: Dec 5, 2025
Valneva SE Revenue
Valneva SE had revenue of 29.41M EUR in the quarter ending September 30, 2025, a decrease of -35.82%. This brings the company's revenue in the last twelve months to 179.91M, up 13.48% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
179.91M
Revenue Growth
+13.48%
P/S Ratio
3.65
Revenue / Employee
252.33K
Employees
713
Market Cap
656.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 27.24B |
| Sanofi | 45.93B |
| Sartorius Stedim Biotech | 2.95B |
| bioMérieux | 4.12B |
| Eurofins Scientific SE | 7.14B |
| Ipsen | 3.76B |
| ABIVAX Société Anonyme | 6.02M |
| Virbac | 1.43B |
Valneva SE News
- 18 hours ago - VALNEVA Declaration of shares and voting rights: November 30, 2025 - GlobeNewsWire
- 9 days ago - Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings - Benzinga
- 9 days ago - Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings - Benzinga
- 9 days ago - Valneva to Further Consolidate its Operations in France - GlobeNewsWire
- 10 days ago - Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study - WSJ
- 10 days ago - Valneva's Lyme Vaccine VLA15 Shows Strong Phase 2 Booster Results With Favorable Safety - Nasdaq
- 10 days ago - Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate - GlobeNewsWire
- 15 days ago - Valneva SE (INRLF) Nine Months 2025 Earnings Call Highlights: Revenue Growth Amid Operational ... - GuruFocus